Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing

SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced it will present three new studies...
September 07, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad RBM’s TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur

SALT LAKE CITY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that...
September 01, 2016 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Completes Acquisition of Assurex Health

SALT LAKE CITY, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) a global leader in personalized medicine, announced today that it has completed its acquisition of Assurex...
August 30, 2016 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference

SALT LAKE CITY, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2016...
August 09, 2016 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results

Total Revenues of $186.5 MillionAdjusted EPS of $0.36 and Diluted EPS of $0.32Company Issues Fiscal First-Quarter 2017 and Fiscal Year 2017 Financial Guidance SALT LAKE CITY, Aug. 09, 2016 ...
August 03, 2016 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health

SALT LAKE CITY, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive...
July 26, 2016 16:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9

SALT LAKE CITY, July 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal fourth-quarter 2016 sales and earnings conference call with...
July 11, 2016 11:24 ET | Source: Myriad Genetics, Inc.

Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute

SALT LAKE CITY and COLOGNE, Germany, July 11, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), in collaboration with researchers from the Institute of Cancer Research in London, today...
June 29, 2016 07:15 ET | Source: Myriad Genetics, Inc.

Myriad’s myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO’s Pivotal Phase 3 Ovarian Cancer Study with Niraparib

SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test...
June 10, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress

SALT LAKE CITY, June 10, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra® DA...